NCT01737424

Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

A Dose Blocked-randomized, Double-blind, Placebo-controlled, Single Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 89 (actual)
• Sponsor: LG Life Sciences · Industry
• Sex: Male
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To investigate the safety, tolerability and pharmacokinetic characteristics of LC28-0126 in healthy male subjects

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LC28-0126	LC28-0126
DRUG	Placebo	Placebo

Timeline

• Start date: 2012-12-01
• Primary completion: 2013-09-01
• Completion: 2013-09-01
• First posted: 2012-11-29
• Last updated: 2014-03-14

Locations

1 site across 1 country: South Korea